 AGOURA HILLS, California, Feb. 01, 2021 GLOBE NEWSWIRE -- Mateon Therapeutics, Inc. OTCQB:MATN Mateon, a leading developer of TGF-β therapeutics for oncology and infectious diseases, announce today that it has launched its artificial intelligence AI telemedicine platform for post marketing survey PMS to support the launch of its drug product, PulmoHealTM. The PMS module, with its previously announced AI mobile app, ArtiHealthTM, rounds out the companys AI telemedicine solution. 